Key Highlights
- Wellumio launches California subsidiary to expand its global presence and conduct U.S.-based clinical trials.
- Axana device offers rapid, portable stroke detection using Pulsed Gradient Free Mapping (PGFM).
- FDA pre-submission meetings complete, moving toward regulatory filings.
- Leadership expansion with Sia Moussavi, Ziad Rouag, and Daniel Weyers joining the team.
Source: PR Newswire
Notable Quote
- “We’ve designed a novel device that is highly portable and significantly faster than traditional MRIs, making it ideal for quick assessments in emergency situations.” — Shieak Tzeng, CEO at Wellumio
Why This Matters
Wellumio’s expansion into California marks a pivotal moment for the company as it accelerates its clinical efforts to bring its groundbreaking stroke detection device, Axana, to the U.S. market. By focusing on portability and speed, Axana promises to significantly improve the speed at which stroke-related brain damage is detected, giving emergency teams vital information during the crucial “golden hour” of stroke treatment. This move, alongside FDA engagement and leadership appointments, positions Wellumio to make a lasting impact on acute stroke care in the U.S. and beyond.
